Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05599347
PHASE2

Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease

Sponsor: Rambam Health Care Campus

View on ClinicalTrials.gov

Summary

This is a randomized placebo-controlled trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity

Official title: Pre-treatment With Azithromycin to Reduce Immunogenicity to Anti-Tumor Necrosis Factor-α Agents in Patients With Crohn's Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

180

Start Date

2023-04-24

Completion Date

2026-12-31

Last Updated

2025-04-04

Healthy Volunteers

No

Interventions

DRUG

Azithromycin Pill

Tablet - 500 mg azithromycin (as dihydrate)

OTHER

Placebo

Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm

Locations (9)

Soroka University Medical Center

Beersheba, Israel

Bnei Zion

Haifa, Israel

Carmel Medical Center

Haifa, Israel

Rambam Health Care Campus

Haifa, Israel

Wolfson Medical Center

Holon, Israel

Hadassah Medical Center

Jerusalem, Israel

Shaare Zedek

Jerusalem, Israel

Zvulun

Kiryat Bialik, Israel

Rabin Medical Center

Petah Tikva, Israel